Center for Scientific Review Notice of Closed Meetings, 25309 [2015-10273]
Download as PDF
<![CDATA[
Federal Register / Vol. 80, No. 85 / Monday, May 4, 2015 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review Notice of
Closed Meetings
mstockstill on DSK4VPTVN1PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Cell Biology
Integrated Review Group; Molecular and
Integrative Signal Transduction Study
Section.
Date: June 1–2, 2015.
Time: 8:00 a.m. to 5:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: Embassy Suites at the Chevy Chase
Pavilion, 4300 Military Road, NW.,
Washington, DC 20015.
Contact Person: Raya Mandler, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5134,
MSC 7840, Bethesda, MD 20892, (301) 402–
8228, rayam@csr.nih.gov.
Name of Committee: Cardiovascular and
Respiratory Sciences Integrated Review
Group; Lung Cellular, Molecular, and
Immunobiology Study Section
Date: June 2–3, 2015.
Time: 7:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Pier 5 Hotel, 711 Eastern Avenue,
Baltimore, MD 21202.
Contact Person: George M Barnas, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 2180,
MSC 7818, Bethesda, MD 20892, 301–435–
0696, barnasg@csr.nih.gov.
Name of Committee: Integrative,
Functional and Cognitive Neuroscience
Integrated Review Group; Sensorimotor
Integration Study Section.
Date: June 2, 2015.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Embassy Suites DC Convention
Center, 900 10th Street, Washington, DC
20001.
Contact Person: John Bishop, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5182,
VerDate Sep<11>2014
19:40 May 01, 2015
Jkt 235001
MSC 7844, Bethesda, MD 20892, (301) 408–
9664, bishopj@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR Panel:
Pilot Clinical Studies in Nephrology and
Urology.
Date: June 2–3, 2015.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Virtual Meeting).
Contact Person: Atul Sahai, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 2188,
MSC 7818, Bethesda, MD 20892, 301–435–
1198, sahaia@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Temporal
dynamics of Neurophysiological Patterns as
Potential Targets for Treating Cognitive
Deficits in Brain Disorders.
Date: June 2, 2015
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Virtual Meeting).
Contact Person: Wei-Qin Zhao, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5181
MSC 7846, Bethesda, MD 20892–7846, 301–
435–1236, zhaow@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: April 28, 2015.
Michelle Trout,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2015–10273 Filed 5–1–15; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive Option
License: The Development of a Single
Domain Human Anti-Mesothelin
Monoclonal Antibody as a Bispecific
Antibody for the Treatment of Human
Cancers.
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
This is notice, in accordance
with 35 U.S.C. 209 and 37 CFR part 404,
that the National Institutes of Health,
Department of Health and Human
Services, is contemplating the grant of
an exclusive start-up option license to
SUMMARY:
PO 00000
Frm 00036
Fmt 4703
Sfmt 4703
25309
practice the inventions embodied in
U.S. Patent Application 61/706,396
entitled ‘‘Mesothelin Antibodies And
Methods For Eliciting Potent Antitumor
Activity’’ [HHS Ref. E–236–2012/0–US–
01], PCT Application PCT/US2013/
059883 entitled ‘‘Mesothelin Antibodies
And Methods For Eliciting Potent
Antitumor Activity’’ [HHS Ref. E–236–
2012/0–PCT–02], and all related
continuing and foreign patents/patent
applications for the technology family,
to Oncolinx Pharmaceuticals, LLC. The
patent rights in these inventions have
been assigned to and/or exclusively
licensed to the Government of the
United States of America.
The prospective exclusive start-up
option licensed territory may be
worldwide, and the field of use may be
limited to:
The use of bispecific antibodies
having:
(a) The complementary determining
regions (CDRs) of the monoclonal
antibody SD1; and
(b) the CDRs of an anti-CD3 antibody,
for the treatment of mesothelinexpressing cancers. The Licensed Field
of Use explicitly excludes the use of the
CDR sequences of SD1 in a
monospecific antibody, or in the form of
an immunotoxin, antibody-drug
conjugate, or chimeric antigen receptor.
Upon the expiration or termination of
the exclusive start-up option license,
Oncolinx Pharmaceuticals, LLC will
have the exclusive right to execute an
exclusive commercialization license
which will supersede and replace the
exclusive start-up option license with
no greater field of use and territory than
granted in the exclusive start-up option
license.
DATES: Only written comments and/or
applications for a license which are
received by the NIH Office of
Technology Transfer on or before May
19, 2015 will be considered.
ADDRESSES: Requests for copies of the
patent application, inquiries, comments,
and other materials relating to the
contemplated exclusive license should
be directed to: David A. Lambertson,
Ph.D., Senior Licensing and Patenting
Manager, Office of Technology Transfer,
National Institutes of Health, 6011
Executive Boulevard, Suite 325,
Rockville, MD 20852–3804; Telephone:
(301) 435–4632; Facsimile: (301) 402–
0220; Email: lambertsond@mail.nih.gov.
SUPPLEMENTARY INFORMATION: This
invention concerns a monoclonal
antibody and methods of using the
antibody for the treatment of
mesothelin-expressing cancers,
including mesothelioma, lung cancer,
ovarian cancer and pancreatic cancer.
E:\FR\FM\04MYN1.SGM
04MYN1
]]>Agencies
[Federal Register Volume 80, Number 85 (Monday, May 4, 2015)]
[Notices]
[Page 25309]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-10273]
[[Page 25309]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Center for Scientific Review Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Cell Biology Integrated Review Group;
Molecular and Integrative Signal Transduction Study Section.
Date: June 1-2, 2015.
Time: 8:00 a.m. to 5:30 p.m.
Agenda: To review and evaluate grant applications.
Place: Embassy Suites at the Chevy Chase Pavilion, 4300 Military
Road, NW., Washington, DC 20015.
Contact Person: Raya Mandler, Ph.D., Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Room 5134, MSC 7840, Bethesda, MD 20892, (301) 402-
8228, rayam@csr.nih.gov.
Name of Committee: Cardiovascular and Respiratory Sciences
Integrated Review Group; Lung Cellular, Molecular, and Immunobiology
Study Section
Date: June 2-3, 2015.
Time: 7:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Pier 5 Hotel, 711 Eastern Avenue, Baltimore, MD 21202.
Contact Person: George M Barnas, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 2180, MSC 7818, Bethesda, MD
20892, 301-435-0696, barnasg@csr.nih.gov.
Name of Committee: Integrative, Functional and Cognitive
Neuroscience Integrated Review Group; Sensorimotor Integration Study
Section.
Date: June 2, 2015.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Embassy Suites DC Convention Center, 900 10th Street,
Washington, DC 20001.
Contact Person: John Bishop, Ph.D., Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Room 5182, MSC 7844, Bethesda, MD 20892, (301) 408-
9664, bishopj@csr.nih.gov.
Name of Committee: Center for Scientific Review Special Emphasis
Panel; PAR Panel: Pilot Clinical Studies in Nephrology and Urology.
Date: June 2-3, 2015.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892, (Virtual Meeting).
Contact Person: Atul Sahai, Ph.D., Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Room 2188, MSC 7818, Bethesda, MD 20892, 301-435-
1198, sahaia@csr.nih.gov.
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Temporal dynamics of Neurophysiological Patterns as Potential
Targets for Treating Cognitive Deficits in Brain Disorders.
Date: June 2, 2015
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892, (Virtual Meeting).
Contact Person: Wei-Qin Zhao, Ph.D., Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Room 5181 MSC 7846, Bethesda, MD 20892-7846, 301-
435-1236, zhaow@csr.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.306,
Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893,
National Institutes of Health, HHS)
Dated: April 28, 2015.
Michelle Trout,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2015-10273 Filed 5-1-15; 8:45 am]
BILLING CODE 4140-01-P
